Preserving vascular integrity during totally robotic sigmoidectomy: unleashing the power of vessel-sparing precision.

BACKGROUND: This study assesses the feasibility, safety, and clinical utility of vessel-sparing approach in totally robotic sigmoidectomy for adenocarcinoma. MATERIAL AND METHODS: A comprehensive protocol for completely vessel-sparing robotic sigmoidectomy (VsRS) was established at the authors' institution from January 2019 through December 2020. Surgical and pathological outcomes were indagated and compared with results of current literature. RESULTS: The study population consisted of 34 patients. The median number of examined lymph nodes (ELN) was 21 (range 15-28); the median number of positive lymph nodes (PLN) was 0 (range 0-8). Mean operative time was 240 min (sd 43.56, range 180-360 min), and conversion to open rate was 0%. Anastomotic leak rate was 0%. The median follow-up period was 28 months CONCLUSION: This pilot series represents a significant step forward in the development of completely vessel-sparing sigmoidectomy for adenocarcinoma. The study demonstrates the safety and feasibility of this innovative approach, which aims to achieve oncological radicality while preserving vital vascular structures. Notably, the postoperative outcomes observed in this study were comparable to those reported in the existing literature for the current standard of care at high-volume centers. Nevertheless, further validation through prospective and controlled investigations is essential before this technique can be fully incorporated into clinical practice.

Intrathoracic Robotic-Sewn Anastomosis During Ivor Lewis Esophagectomy for Cancer: Back to Basics?

BACKGROUND: To assess the feasibility, clinical utility, and safety of intrathoracic robotic-sewn esophageal anastomosis (IrEA) during Ivor Lewis esophagectomy for adenocarcinoma of the lower third of the esophagus, or cancer at the gastro-esophageal junction type I (Siewert classification). METHODS: A protocol for completely robotic Ivor Lewis esophagectomy (CrIE) and intrathoracic robotic-sewn anastomosis (IrEA) was established at the authors' institutions from January 2015 through December 2019. Overall surgery-related postoperative complications were analyzed. Overall survival and disease-free survival analysis were performed using standard methods. RESULTS: The study population consisted of 40 patients. Median operative time was 320 min (sd 62, range 235-500 min), and conversion to open rate was 0%. Anastomotic leak rate was 10%. The mean number of examined lymph nodes (ELN) was 19 (IQR 11-29), and the mean number of positive lymph nodes (PLN) was 3 (IQR 0-5). Short- and long-term surgical and oncological outcomes were comparable at a medium follow-up of 37 months. The median overall survival was 48 months while the mean disease-free survival was 29 months. CONCLUSION: This pilot series, in which an intrathoracic robotic-sewn anastomosis (IrEA) was performed during CrIE, demonstrated the safety and feasibility of this approach. Compared to the current standard of care at a high-volume center, IrEA was associated with better postoperative surgical outcomes and similar oncological outcomes to those reported worldwide today. These results call for further validation in a prospective and controlled setting to be fully incorporated into clinical practice.